News | Stents Bioresorbable | October 11, 2022

Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

Grant Proceeds Will Support Pre-Clinical Studies

Grant Proceeds Will Support Pre-Clinical Studies

October 11, 2022 —  Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health. SBIR grants are intended to stimulate technological innovation and encourage small United States businesses to engage in R&D with the potential for commercialization. The objective of Phase II grants is to continue the R&D efforts started under Phase I, in which the technical merit, feasibility, commercial potential of a project, and the quality of performance of the small business awardee have been established. Funds from Efemoral's award will be applied towards conducting studies aimed at characterizing the pre-clinical safety, efficacy, and foundational mechanism of action of its unique device. 

The Efemoral Vascular Scaffold System (EVSS) with FlexStep Technologyoffers a new approach for treating peripheral arterial disease (PAD) by addressing the specific anatomical challenges and complex biomechanics of patients with athero-occlusive disease in the leg. Using a combination of rigid scaffolds and inter-scaffold spaces, the patented FlexStep Technology combines flexibility with support to accommodate tortuosity and skeletal movement, while the balloon-expandable deployment system easily opens vessels and sustains healthy blood flow. The novel bioresorbable scaffold with long-term sirolimus elution aims to restore normal vessel diameter during the procedure, deliver therapeutic benefits across all lesion lengths and morphologies, prevent restenosis, and maintain patency while leaving no permanent implant behind. 

"Current treatment options for patients with peripheral occlusive disease are woeful as early failures are common and the results continue to degrade over time," said Lewis B. Schwartz, MD, Co-Founder and CMO of Efemoral Medical. "The EVSS uses a unique design of alternating dissolvable scaffolds and spaces that enables the long arteries of the legs to be treated with the same, effective, balloon-expandable technology proven to be successful in other human vascular beds. It's time that we stopped implanting metal into our patient's arteries." 

PAD, also known as "poor circulation" or "hardening of the arteries," is a global plague. It affects approximately 200 million people worldwide1, including an estimated 20 million in the United States.2 Left untreated, PAD can lead to severe disability and extremity amputation. The effectiveness of current interventional treatment remains limited with up to 50% of conventional endovascular procedures complicated by failure or recurrence within the first year.3 

"We are honored and grateful to receive this competitive award that came as a result of a rigorous scientific assessment of the technical and commercial potential of our device from a panel of subject matter experts," said Christopher Haig, Co-Founder and CEO of Efemoral Medical. "Funding from this award will allow us to complement our ongoing clinical work with additional pre-clinical evidence as we endeavor to bring this intravascular technology to the U.S. We are looking forward to building a robust body of evidence that demonstrates the potential of our device to reliably and durably treat PAD without the need for a permanent implant." 

For more information: efemoralmedical.com 

References: 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377796/ 

2 Yost, The True Prevalence of PAD and the Economics of Major Amputation, Endovascular Today, May 2021 

https://www.researchgate.net/publication/260118801_Nitinol_Self-Expanding_Stents_vs_Balloon_Angioplasty_for_Very_Long_Femoropopliteal_Lesions 


Related Content

News | Stents Bioresorbable

March 16, 2023 — Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the ...

Home March 16, 2023
Home
News | Stents Bioresorbable

September 28, 2022 — In the "TCT Innovation" session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator ...

Home September 28, 2022
Home
News | Stents Bioresorbable

September 27, 2022 — BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster ...

Home September 27, 2022
Home
News | Stents Bioresorbable

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

Home December 16, 2020
Home
Feature | Stents Bioresorbable

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

Home September 03, 2020
Home
News | Stents Bioresorbable

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due ...

Home November 07, 2019
Home
Feature | Stents Bioresorbable | Dave Fornell, Editor

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...

Home October 12, 2018
Home
News | Stents Bioresorbable

October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom ...

Home October 12, 2018
Home
News | Stents Bioresorbable

October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (TCT ...

Home October 01, 2018
Home
Videos | Stents Bioresorbable

Patrick Serruys, M.D., Ph.D., Imperial College London, explains where development of bioresorbable scaffolds stands in ...

Home August 06, 2018
Home
Subscribe Now